BioCentury
ARTICLE | Clinical News

FDA approves Icon Bioscience's Dexycu

February 23, 2018 8:16 PM UTC

Icon Bioscience Inc. (Sunnyvale, Calif.) said FDA approved an NDA for Dexycu dexamethasone intraocular suspension to treat inflammation associated with cataract surgery...

BCIQ Company Profiles

Icon Bioscience Inc.